ARMP
Armata Pharmaceuticals, Inc.Company Information
- Company Name
- Armata Pharmaceuticals, Inc.
- CIK
- CIK0000921114
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ARMP: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ARMP
SEC filing data through
Insider Sentiment
- Last purchase
- 2022-03-31
- Last sale
- —
- Shares purchased (TTM)
- 10,212,122
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 5,010,511
- Shares outstanding
- 36,747,840
- Ownership
- 13.63%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 35.50%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 24 | 5 | 9 | 15 | 4 | 12 | 9 | 17 | 26 | 38 | 14 | 24 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | - | 4 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 2 | - | ||||||
| Other Assets Current | 3 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 1 | 2 | 3 | 8 | ||||||
| Assets Current | 27 | 6 | 11 | 17 | 8 | 13 | 11 | 22 | 31 | 42 | 19 | 37 | ||||||
| Restricted Cash Noncurrent | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | ||||||
| Property Plant And Equipment Net | 11 | 12 | 12 | 13 | 13 | 13 | 13 | 14 | 13 | 13 | 13 | 9 | ||||||
| Operating Lease Right Of Use Asset | 33 | 33 | 34 | 40 | 41 | 41 | 42 | 42 | 44 | 44 | 45 | 45 | ||||||
| Intangible Assets Net Excluding Goodwill | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Goodwill | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Assets | 90 | 70 | 77 | 90 | 81 | 87 | 86 | 98 | 108 | 120 | 98 | 113 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 5 | 6 | 7 | ||||||
| Deferred Compensation Liability Current | 2 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | ||||||
| Convertible Debt Current | 164 | - | - | 48 | 33 | 28 | - | 41 | 48 | 72 | - | - | ||||||
| Operating Lease Liability Current | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 5 | 7 | 7 | 9 | 13 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | - | ||||||
| Liabilities Current | 250 | 9 | 9 | 140 | 120 | 111 | 48 | 118 | 123 | 110 | 16 | 22 | ||||||
| Convertible Debt Noncurrent | - | 255 | 154 | - | - | - | 33 | - | - | - | 59 | 50 | ||||||
| Secured Long Term Debt | 42 | 88 | 103 | 15 | - | - | 23 | - | - | 35 | 24 | 22 | ||||||
| Operating Lease Liability Noncurrent | 26 | 26 | 27 | 27 | 27 | 27 | 28 | 28 | 28 | 28 | 29 | 28 | ||||||
| Deferred Income Tax Liabilities Net | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities | 321 | 381 | 295 | 185 | 150 | 141 | 134 | 149 | 154 | 177 | 130 | 125 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 311 | 305 | 283 | 281 | 281 | 280 | 279 | 279 | 278 | 277 | 276 | 276 | ||||||
| Retained Earnings Accumulated Deficit | -543 | -617 | -502 | -377 | -351 | -334 | -328 | -330 | -325 | -334 | -309 | -289 | ||||||
| Stockholders Equity | -231 | -312 | -219 | -96 | -70 | -54 | -48 | -51 | -46 | -57 | -32 | -12 | ||||||
| Liabilities And Stockholders Equity | 90 | 70 | 77 | 90 | 81 | 87 | 86 | 98 | 108 | 120 | 98 | 113 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | ||||||
| Common Stock Shares Issued | 37 | 37 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | ||||||
| Shares Outstanding | 37 | - | 36 | 4 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialArmata Pharmaceuticals, Inc. (ARMP) — SEC Financial Statements & Analysis
Armata Pharmaceuticals, Inc. (ARMP) is a biological products, (no diagnostic substances) company, incorporated in WA. Armata Pharmaceuticals, Inc. trades on NYSE as: ARMP. Armata Pharmaceuticals, Inc. (ARMP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Armata Pharmaceuticals, Inc. carries a market cap of $238.13M, a P/E ratio of -1.24x, a P/B ratio of -1.03x, an enterprise value of $415.98M, and an EV/EBITDA multiple of -10.57x. On profitability, it posts a Return on Equity (ROE) of 127.83%, a Return on Assets (ROA) of -225.11%, and a Return on Invested Capital (ROIC) of -433.72%. Per share, it reports EPS of $-5.23, diluted EPS of $-3.10, free cash flow per share of $-0.70, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 647.57% year-over-year and EPS growth of 636.29% year-over-year. On the balance sheet, it maintains a current ratio of 0.11x, a quick ratio of 0.11x, working capital of $-223.04M, a debt-to-equity ratio of -1.39x, a debt ratio of 3.57, an interest coverage ratio of -14.86x, free cash flow of $-25.79M (TTM), and net debt of $177.86M. Figures sourced from SEC EDGAR.
- Market Cap
- $238.13M
- P/E TTM
- -1.24x
- EPS TTM
- $-5.23
- P/B TTM
- -1.03x
- ROE TTM
- 127.83%
- ROA TTM
- -225.11%
- Debt To Equity
- -1.39x
- Free Cash Flow TTM
- $-25.79M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Armata Pharmaceuticals, Inc. in?
Armata Pharmaceuticals, Inc. (ARMP) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ARMP trade on?
Armata Pharmaceuticals, Inc. (ARMP) trades on the NYSE.
Where is Armata Pharmaceuticals, Inc. incorporated?
Armata Pharmaceuticals, Inc. is incorporated in WA.
When was Armata Pharmaceuticals, Inc. (ARMP)'s most recent SEC filing?
Armata Pharmaceuticals, Inc. (ARMP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is ARMP's market cap?
Armata Pharmaceuticals, Inc. (ARMP) has a market capitalization of $238.13M as of 2026-06-30.
What is ARMP's EPS (earnings per share)?
Armata Pharmaceuticals, Inc. (ARMP)'s trailing twelve month EPS is $-5.23 as of 2026-06-30.
What is ARMP's ROE (return on equity)?
Armata Pharmaceuticals, Inc. (ARMP)'s trailing twelve month Return on Equity (ROE) is 127.83% as of 2026-06-30.
What is ARMP's ROA (return on assets)?
Armata Pharmaceuticals, Inc. (ARMP)'s trailing twelve month Return on Assets (ROA) is -225.11% as of 2026-06-30.
What is ARMP's ROIC (return on invested capital)?
Armata Pharmaceuticals, Inc. (ARMP)'s trailing twelve month Return on Invested Capital (ROIC) is -433.72% as of 2025-12-31.
What is ARMP's EV/EBITDA?
Armata Pharmaceuticals, Inc. (ARMP)'s trailing twelve month EV/EBITDA is -10.57x as of 2026-06-30.